Dr. Gross received support from a Research Scholar Grant, RSG-14-029-01-CPHPS from the American Cancer Society, and receives support from Medtronic, Inc., Johnson & Johnson, Pfizer, and Century Oncology. Dr. Abu-Khalaf receives research support from Genentech, Novartis, Merck, Merrimack, and Clovis Oncology; these supports were not used for any portion of the manuscript. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Elmore JG, Nakano CY, Linden HM et al.. Racial inequities in the timing of breast cancer detection, diagnosis, and initiation of treatment. Med Care 2005;43:141–148.
Fedewa SA, Ward EM, Stewart AK, Edge SB. Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic ppoulations: a national cohort study 2004-2006. J Clin Oncol 2010;28:4135–4141.
Adams SA, Smith ER, Hardin J et al.. Racial differnces in follow-up of abnormal mammography findings among economically disadvantaged women. Cancer 2009;115:5788–5797.
Bickell NA, Wang JJ, Oluwole S et al.. Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol 2006;24:1357–1362.
McCarthy EP, Burns RB, Coughlin SS et al.. Mammography use helps to explain differences in breast cancer stage at diagnosis between older black and white women. Ann Intern Med 1998;128:729–736.
van Ravesteyn NT, Schechter CB, Near AM et al.. Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States. Cancer Epidemiol Biomarkers Prev 2011;20:112–122.
Tehranifar P, Neugut AI, Phelan JC, Link BG et al.. Medical advances and racial/ethnic disparities in cancer survival. Cancer Epidemiol Biomarkers Prev 2009;18:2701–2708.
Paik S, Tang G, Shak S et al.. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726–3734.
Gradishar WJ, Anderson BO, Blair SL et al.. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, version 3.2014. Accessed September 14, 2014. To view the most recent version of these guidelines, visit NCCN.org.
Carlson RW, Allred DC, Anderson BO et al.. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009;7:122–192.
Gradishar WJ, Anderson BO, Balassanian R et al.. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, version 3.2015. Accessed October 10, 2016. To view the most recent version of these guidelines, visit NCCN.org.
Su KW, Hall J, Soulos PR et al.. Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008-2011. J Geriatric Oncol 2016;7:15–23.
Sheppard VB, O'Neill SC, Dilawari A et al.. Patterns of 21-gene assay testing and chemotherapy use in black and white breast cancer patients. Clin Breast Cancer 2015;15:e83–92.
Roberts MC, Weinberger M, Dusetzina SB et al.. Racial variation in the uptake of Oncotype DX testing for early-stage breast cancer. J Clin Oncol 2016;34:130–138.
Lund MJ, Mosunjac M, Davis KM et al.. 21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome. Cancer 2012;118:788–796.
Hassett MJ, Silver SM, Hughes ME et al.. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol 2012;30:2218–2226.
Haas JS, Phillips KA, Liang SY et al.. Genomic testing and therapies for breast cancer in clinical practice. J Clin Oncol 2011;7(3 Suppl):e1s–7s.
Guth AA, Fineberg S, Fei K et al.. Utilization of Oncotype DX in an inner city population: race or place? Int J Breast Cancer 2013;2013:653805.
Dinan MA, Mi X, Reed SD et al.. Initial trends in the use of the 21-gene recurrence score assay for patients with breast cancer in the Medicare population, 2005-2009. JAMA Oncol 2015;1:158–166.
DeFrank JT, Salz T, Reeder-Hayes K, Brewer NT. Who gets genomic testing for breast cancer recurrence risk? Public Health Genomics 2013;16:215–222.
Jasem J, Amini A, Rabinovitch R et al.. 21-gene recurrence score assay as a predictor of adjuvant chemotherapy administration for early-stage breast cancer: an analysis of use, therapeutic implications, and disparity profile. J Clin Oncol 2016;34:1995–2002.
Cress RD, Chen YS, Morris CR et al.. Underutilization of gene expression profiling for early-stage breast cancer in California. Cancer Causes Control 2016;27:721–727.
O'Neill SC, Isaacs C, Chao C et al.. Adoption of gene expression profiling for breast cancer in US oncology practice for women younger than 65 years. J Natl Compr Canc Netw 2015;13:1216–1224.
Gaskin DJ, Dinwiddie GY, Chan KS, McCleary R. Residential segregation and disparities in health care services utilization. Med Care Res Rev 2011;69:158–175.
Saloner B, Lê Cook B. Blacks and Hispanics are less likely than whites to complete addiction treatment, largely due to socioeconomic factors. Health Aff (Millwood) 2013;32:135–145.